Ratnakar Securities Pvt. Ltd.

EMCURE PHARMACEUTICALS LTD.

NSE : EMCUREBSE : 544210ISIN CODE : INE168P01015Industry : Pharmaceuticals & DrugsHouse : Private

BSE1463.00-63.6 (-4.17 %)

PREV CLOSE ( ) 1526.60

OPEN PRICE ( ) 1539.35

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 19663

TODAY'S LOW / HIGH ( )1440.30 1539.95

52 WK LOW / HIGH ( )1226.5 1577.5

BSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 16-04 1981

Management Info

Berjis Minoo Desai - Chairman Satish Ramanlal Mehta - Managing Director

Registered Office

Address Plot No. P-1 & P-2,I T - B T Park, Phase- I I,M I D C, Hinjawadi,
Pune,
Maharashtra-411057

Phone 020-3507003 / 35070000

Email investors@emcure.com

Website www.emcure.com

Registrars Details

Link Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

16Sep Emcure Pharmaceuticals inches up on ge
Emcure Pharmaceuticals is currently trading at Rs. 1421.30, up by 0.65 p..

14Sep Emcure Pharmaceuticals gets nod to inc
Emcure Pharmaceuticals has received approval for the incorporation of a..

06Sep Emcure Pharmaceuticals launches produc
Emcure Pharmaceuticals has launched a product range aimed at supporting..

26Jul Emcure Pharmaceuticals signs Power Pur
Emcure Pharmaceuticals together with its subsidiary Gennova Biopharmaceu..

10Jul Emcure Pharmaceuticals lists with 31%
Emcure Pharmaceuticals has debuted at Rs 1325.05 on the BSE, up by 317.0..

Financials

in Millions

	QTR Jun 24	ANNUAL
Net Profit	404.459999999999
Gross Profit	550.479999999999
Operating Profit	1476.94
Net Sales

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 27963.25 (0.60%)	M.Cap ( in Cr)59419.95
Ajanta Pharma (BSE) 3204.60 (2.61%)	M.Cap ( in Cr)40029.33
Concord Biotech (BSE) 2258.20 (3.33%)	M.Cap ( in Cr)23624.43
Wockhardt (BSE) 1004.45 (5.00%)	M.Cap ( in Cr)15409.22
Alkem Laboratories (BSE) 6138.30 (0.77%)	M.Cap ( in Cr)73392.58

Shareholding Pattern

	PROMOTERS	0%
	MUTUAL FUNDS/UTI	0%
	FI/BANKS/INSURANCE	0%
	GOVERNMENT	0%
	FII	0%
	NON-INSTITUTION	0%

Mf Holdings

Scheme Name	Hold(%)
No Data Found

attention investors
kyc
ipo
ibt trading
KYC & KRA Status Awareness

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

Ratnakar Securities

Smart Quotes

EMCURE PHARMACEUTICALS LTD.

Filing complaints on SCORES Easy & quick

RISK DISCLOSURES ON DERIVATIVES